Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
5.
Mycoses ; 63(2): 189-196, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31724251

ABSTRACT

BACKGROUND: Lanoconazole (LCZ) is a topical antifungal agent clinically used to treat fungal infections such as tinea pedis. LCZ has not only antifungal effects but also anti-inflammatory effects, which have the potential to provide additional clinical benefits. However, the characteristic features of the inhibitory effects of LCZ on skin inflammation remain unclear. OBJECTIVE: We evaluated the inhibitory effects of topical application of LCZ, and compared the effects of LCZ with those of other antifungal agents including liranaftate, terbinafine and amorolfine. METHODS: Each antifungal agent was topically applied on 12-O-tetradecanoylphorbol-13-acetate-induced irritant dermatitis and 2,4,6-trinitrophenyl chloride-induced contact dermatitis in mice (BALB/c). The ear thickness, myeloperoxidase activity and inflammatory mediator contents were evaluated. RESULTS: LCZ dose-dependently suppressed 12-O-tetradecanoylphorbol-13-acetate-induced irritant dermatitis, suppressed the production of neutrophil chemotactic factors such as keratinocyte-derived chemokine and macrophage inflammatory protein-2, and inhibited neutrophil infiltration to the inflammation site. Moreover, 1% LCZ reduced the ear swelling in mice with 2,4,6-trinitrophenyl chloride-induced contact dermatitis in accordance with the inhibition of interferon-γ production. The inhibitory potency of LCZ on these types of dermatitis in mice was stronger than that of other types of antifungal agents. CONCLUSION: The anti-inflammatory effects of LCZ were exerted through the inhibition of inflammatory mediator production. These effects may contribute to the relief of dermatitis symptoms in patients with tinea pedis.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Dermatitis, Contact/drug therapy , Imidazoles/therapeutic use , Picrates/adverse effects , Tetradecanoylphorbol Acetate/adverse effects , Tinea Pedis/pathology , Animals , Antifungal Agents/therapeutic use , Dermatitis, Contact/etiology , Dermatitis, Contact/prevention & control , Dose-Response Relationship, Drug , Ear, External/drug effects , Ear, External/pathology , Female , Mice , Mice, Inbred BALB C , Tinea Pedis/complications
6.
Hautarzt ; 70(8): 581-593, 2019 Aug.
Article in German | MEDLINE | ID: mdl-31172201

ABSTRACT

BACKGROUND: Foot mycoses, including onychomycoses, are worldwide infectious diseases. As part of a regional survey using randomly selected residents of in Mecklenburg-Western Pomerania, we investigated the impact of dietary habits, the presence of most frequent autoimmune diseases and current smoking on fungal skin infections in order to reveal potential new risk factors to elucidate potential preventive interventions. OBJECTIVES: The identification of potential new factors that influence the development of mycosis was performed in order to derive possible preventive measures. METHODS: In the Study of Health in Pomerania (SHIP) in Mecklengburg-Western Pomerania, 2523 inhabitants were examined for mycotic lesions and asked about nutritional habits, the presence of atopic dermatitis, allergic rhinitis, psoriasis and smoking habits. RESULTS: In all, 8% of probands were diagnosed with mycosis, 6.5% onychomycosis, 3.7% tinea pedis and 0.2% tinea corporis. Psoriasis, allergic rhinitis and atopic dermatitis and frequent consumption of cooked potatoes, oatmeal and corn flakes, cereals, pasta and rice were significantly associated with tinea pedis. Onychomycosis was positively associated with consumption of cooked potatoes. Cigarette consumption proved protective for tinea pedis and dermatophyte colonization. CONCLUSIONS: The autoimmune disorders psoriasis and atopic dermatitis and allergic rhinitis seem to predispose to foot mycosis. Recalcitrant mycosis should raise the question of diets high in carbohydrates. Nicotine abuse seems to protect against skin mycosis and colonization.


Subject(s)
Dermatitis, Atopic/complications , Feeding Behavior , Onychomycosis/complications , Psoriasis/complications , Rhinitis, Allergic/complications , Smoking/adverse effects , Tinea Pedis/complications , Autoimmune Diseases , Dermatitis, Atopic/epidemiology , Germany/epidemiology , Humans , Incidence , Onychomycosis/epidemiology , Psoriasis/epidemiology , Rhinitis, Allergic/epidemiology , Tinea Pedis/epidemiology
7.
Wilderness Environ Med ; 30(1): 93-95, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30718137

ABSTRACT

Skin infections are an important issue among participants in expedition-length adventure races. Prolonged stress, scant sleep, and water exposure mean that competitors are at risk of uncommon manifestations of infections. Ulcerative tinea pedis is an example of this. We present a case with characteristic clinical manifestations, including the "sandpaper symptom." There is limited literature exploring infectious foot complaints in expedition adventure racers. Beyond this case report, more research is needed to better understand incidence rates, risk factors, diagnostic measures, treatment, and prevention options.


Subject(s)
Skin Ulcer/etiology , Skin Ulcer/pathology , Sports , Tinea Pedis/complications , Tinea Pedis/pathology , Adult , Expeditions , Humans , Male , Skin Ulcer/drug therapy , Tinea Pedis/drug therapy
9.
Infez Med ; 25(4): 377-380, 2017 Dec 01.
Article in English | MEDLINE | ID: mdl-29286021

ABSTRACT

A remarkable case of onychomycosis by Trichophyton (T.) rubrum combined with nail infestation by Tyrophagus (T.) putrescentiae in an elderly diabetic farmer is described and discussed. Large numbers of eggs and mites in all development stages were present in nail debris, reflecting active reproduction on site. Treatment with ivermectin 0.1% cream and environmental decontamination cleared the mite infestation, while onychomycosis responded well to oral terbinafine and ciclopirox 8% nail lacquer. Such a combination of onychomycosis and mite infestation of the same nail is an exceptional finding reported only twice in the literature.


Subject(s)
Foot Dermatoses/complications , Mite Infestations/complications , Nails/parasitology , Onychomycosis/complications , Tinea Pedis/complications , Trichophyton/isolation & purification , Aged , Agricultural Workers' Diseases/drug therapy , Agricultural Workers' Diseases/microbiology , Animal Husbandry , Antifungal Agents/therapeutic use , Ciclopirox , Diabetes Mellitus, Type 2/complications , Disease Susceptibility , Foot Dermatoses/microbiology , Humans , Ivermectin/therapeutic use , Male , Naphthalenes/therapeutic use , Onychomycosis/microbiology , Permethrin , Pyridones/therapeutic use , Shoes , Terbinafine , Tinea Pedis/microbiology
10.
J Drugs Dermatol ; 16(2): 105-109, 2017 02 01.
Article in English | MEDLINE | ID: mdl-28300851

ABSTRACT

Fungal infection of the nails is an increasingly recognized disease in infants and children. However, it can be difficult to distinguish clinically from other nail dystrophies. In addition, many mistakenly believe that onychomycosis does not occur in childhood. Under-recognition of this infectious disorder therefore occurs. Although many consider "nail fungus" a trivial cosmetic concern, it can lead to discomfort, risk of secondary infection, and a more significant health threat in immunocompromised or diabetic individuals. It should always be considered in the differential diagnosis of nail plate disorders in children as it is one of the more common causes.

Here we review the latest data on prevalence of the disease, reasons for its relatively low incidence compared with adults, and important predisposing factors. It is important to confirm the clinical diagnosis of onychomycosis in children, and affected individuals should be examined for concomitant tinea pedis. As familial disease often occurs, it is important to check parents and siblings as well for onychomycosis and tinea pedis.

Treatment of onychomycosis is challenging, and recurrence appears to be more common in children than in adults. Prolonged systemic antifungal therapy is commonly required. However, pediatric practitioners and parents alike hesitate when asked to treat young children with a systemic drug that requires laboratory monitoring and can have systemic toxicities. Due to their thinner, faster-growing nails, children are theoretically more likely to respond to topical monotherapy than adults, and therefore good candidates for topical antifungal therapy.

The clinical data on the use of topical antifungals in pediatric onychomycosis is scarce. We review data that exist from case reports and small clinical trials. New topical antifungals are now available that afford better nail penetration and additional delivery routes to the site of infection. Pediatric trials are now on-going, and should clarify the usefulness of these agents in children.


Subject(s)
Antifungal Agents/administration & dosage , Onychomycosis/diagnosis , Onychomycosis/drug therapy , Tinea Pedis/diagnosis , Administration, Topical , Adult , Age Factors , Antifungal Agents/adverse effects , Child , Ciclopirox , Family , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Incidence , Ketoconazole/administration & dosage , Ketoconazole/adverse effects , Lacquer , Morpholines/administration & dosage , Morpholines/adverse effects , Naphthalenes/administration & dosage , Naphthalenes/adverse effects , Onychomycosis/complications , Onychomycosis/epidemiology , Prevalence , Pyridones/administration & dosage , Pyridones/adverse effects , Recurrence , Terbinafine , Tinea Pedis/complications , Treatment Outcome
11.
Br J Dermatol ; 177(2): 382-394, 2017 Aug.
Article in English | MEDLINE | ID: mdl-27864837

ABSTRACT

Nonpurulent cellulitis is an acute bacterial infection of the dermal and subdermal tissues that is not associated with purulent drainage, discharge or abscess. The objectives of this systematic review and meta-analysis were to identify and appraise all controlled observational studies that have examined risk factors for the development of nonpurulent cellulitis of the leg (NPLC). A systematic literature search of electronic databases and grey literature sources was performed in July 2015. The Newcastle-Ottawa Scale (NOS) was used to assess methodological quality of included studies. Of 3059 potentially eligible studies retrieved and screened, six case-control studies were included. An increased risk of developing NPLC was associated with previous cellulitis [odds ratio (OR) 40·3, 95% confidence interval (CI) 22·6-72·0], wound (OR 19·1, 95% CI 9·1-40·0), current leg ulcers (OR 13·7, 95% CI 7·9-23·6), lymphoedema/chronic leg oedema (OR 6·8, 95% CI 3·5-13·3), excoriating skin diseases (OR 4·4, 95% CI 2·7-7·1), tinea pedis (OR 3·2, 95% CI 1·9-5·3) and body mass index > 30 kg m-2 (OR 2·4, 95% CI 1·4-4·0). Diabetes, smoking and alcohol consumption were not associated with NPLC. Although diabetics may have been underrepresented in the included studies, local risk factors appear to play a more significant role in the development of NPLC than do systemic risk factors. Clinicians should consider the treatment of modifiable risk factors including leg oedema, wounds, ulcers, areas of skin breakdown and toe-web intertrigo while administering antibiotic treatment for NPLC.


Subject(s)
Cellulitis/etiology , Skin Diseases, Bacterial/etiology , Alcohol Drinking/adverse effects , Humans , Leg Injuries/complications , Leg Ulcer/etiology , Lymphedema , Obesity/complications , Observational Studies as Topic , Recurrence , Risk Factors , Smoking/adverse effects , Tinea Pedis/complications
12.
Dermatol Online J ; 22(12)2016 Dec 15.
Article in English | MEDLINE | ID: mdl-28329539

ABSTRACT

Gyrate erythema, which also is known as erythemaannulare centrifugum (EAC), is a reactive dermatitisthat is thought to occur in response to an underlyingtrigger. The superficial form is characterized bythe typical, centrifugally-expanding, annular,erythematous patches or plaques with a distincttrailing scale. The deep form also is a centrifugallyexpanding,erythematous plaque but with induratedborders and absence of scale. These cutaneousfindings are thought to be reactive, most often inresponse to infections or drugs and, less likely, tounderlying malignant conditions.


Subject(s)
Erythema/diagnosis , Skin Diseases, Genetic/diagnosis , Tinea Pedis/diagnosis , Abdomen , Back , Erythema/complications , Erythema/pathology , Humans , Male , Middle Aged , Skin Diseases, Genetic/complications , Skin Diseases, Genetic/pathology , Tinea Pedis/complications
13.
J Am Podiatr Med Assoc ; 105(5): 407-11, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26429609

ABSTRACT

BACKGROUND: We sought to evaluate the efficacy of efinaconazole topical solution, 10%, in patients with onychomycosis and coexisting tinea pedis. METHODS: We analyzed 1,655 patients, aged 18 to 70 years, randomized (3:1) to receive efinaconazole topical solution, 10%, or vehicle from two identical multicenter, double-blind, vehicle-controlled 48-week studies evaluating safety and efficacy. The primary end point was complete cure rate (0% clinical involvement of the target toenail and negative potassium hydroxide examination and fungal culture findings) at week 52. Three groups were compared: patients with onychomycosis and coexisting interdigital tinea pedis on-study (treated or left untreated) and those with no coexisting tinea pedis. RESULTS: Treatment with efinaconazole topical solution, 10%, was significantly more effective than vehicle use irrespective of the coexistence of tinea pedis or its treatment. Overall, 352 patients with onychomycosis (21.3%) had coexisting interdigital tinea pedis, with 215 of these patients (61.1%) receiving investigator-approved topical antifungal agents for their tinea pedis in addition to their randomized onychomycosis treatment. At week 52, efinaconazole complete cure rates of 29.4% were reported in patients with onychomycosis when coexisting tinea pedis was treated compared with 16.1% when coexisting tinea pedis was not treated. Both cure rates were significant compared with vehicle (P = .003 and .045, respectively), and in the latter subgroup, no patients treated with vehicle achieved a complete cure. CONCLUSIONS: Treatment of coexisting tinea pedis in patients with onychomycosis enhances the efficacy of once-daily topical treatment with efinaconazole topical solution, 10%.


Subject(s)
Onychomycosis/drug therapy , Tinea Pedis/drug therapy , Triazoles/administration & dosage , Administration, Topical , Adolescent , Adult , Aged , Antifungal Agents/administration & dosage , Double-Blind Method , Female , Follow-Up Studies , Humans , Male , Middle Aged , Onychomycosis/complications , Tinea Pedis/complications , Treatment Outcome , Young Adult
14.
J Drugs Dermatol ; 14(5): 492-4, 2015 May.
Article in English | MEDLINE | ID: mdl-25942668

ABSTRACT

Onychomycosis is a common nail infection that often co-exists with tinea pedis. Surveys have suggested the diseases co-exist in at least one third of patients, although actual numbers may be a lot higher due to significant under-reporting. The importance of evaluating and treating both diseases is being increasingly recognized, however, data on improved outcomes, and the potential to minimize re-infection are limited. We review a recent post hoc analysis of two large studies treating mild to moderate onychomycosis with efinaconazole topical solution, 10%, demonstrating that complete cure rates of onychomycosis are significantly improved when any co-existing tinea pedis is also treated.


Subject(s)
Antifungal Agents/administration & dosage , Tinea Pedis/drug therapy , Triazoles/administration & dosage , Administration, Topical , Antifungal Agents/therapeutic use , Clinical Trials as Topic , Humans , Onychomycosis/drug therapy , Onychomycosis/epidemiology , Severity of Illness Index , Tinea Pedis/complications , Triazoles/therapeutic use
15.
J Am Podiatr Med Assoc ; 104(5): 544-7, 2014.
Article in English | MEDLINE | ID: mdl-25275748

ABSTRACT

Nodular amyloidosis is a protein deposition disorder that is important to recognize in the clinical setting. Identification and differentiation from primary systemic amyloidosis, which has an identical cutaneous presentation, but serious systemic implications, is of particular significance. Our case report highlights two patients who presented with isolated involvement of the plantar surface and ungual phalanges, each with concomitant tinea pedis. Recognition and diagnosis of cutaneous amyloidosis enables discrimination from systemic disease, and if found, prompt institution of appropriate treatment.


Subject(s)
Amyloidosis/diagnosis , Foot Diseases/diagnosis , Aged , Amyloidosis/complications , Foot Diseases/complications , Humans , Male , Middle Aged , Tinea Pedis/complications
16.
Clin Dermatol ; 32(5): 621-7, 2014.
Article in English | MEDLINE | ID: mdl-25160103

ABSTRACT

Recurrent lymphangitic cellulitis syndrome (RLCS) occurs when a disordered lymphatic system renders a leg vulnerable to recurrent infection. The underlying immunologic defect is the result of accidental or iatrogenic penetrating wounds on the medial aspect of the thigh or lower limb overlying the greater saphenous vein, because the primary lymphatic drainage vessels are adjacent to this structure. Cracking/fissuring of the skin associated with chronic fungal infection of the feet ("athlete's foot"), most commonly mixed bacterial/fungal interdigital involvement, provides a portal of entry for opportunistic organisms. Bacteria and their products are cleared more slowly in the lymphatic-disrupted and therefore immunologically impaired limb, producing broad areas of dermatitis and around the scars quite distinct from other forms of superficial infection. This rarely develop in otherwise normal limbs. The dermatitis of RLCS and its systemic effects clear with antibiotics but recur intermittently until the tinea pedis is eradicated. The contralateral limb with normal lymphatic structures never develops clinical evidence of infection even though bilateral tinea infection is almost always present. This confirms the central role of an anatomically induced immunocompromised district (ICD) in this syndrome.


Subject(s)
Cellulitis/immunology , Immunocompromised Host , Lymphatic Diseases/complications , Lymphatic Diseases/immunology , Cellulitis/diagnosis , Humans , Recurrence , Syndrome , Tinea Pedis/complications , Tinea Pedis/immunology
17.
Cutan Ocul Toxicol ; 33(4): 339-41, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24641119

ABSTRACT

A 27-year-old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole. The patient was diagnosed with drug-induced baboon syndrome based on his history, which included prior sensitivity to topical ketoconazole, a physical examination, and histopathological findings. Baboon syndrome is a drug- or contact allergen-related maculopapular eruption that typically involves the flexural and gluteal areas. To the best of our knowledge, this is the first reported case of ketoconazole-induced baboon syndrome in the English literature.


Subject(s)
Antifungal Agents/adverse effects , Drug Eruptions/pathology , Ketoconazole/adverse effects , Administration, Topical , Adult , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Buttocks , Erythema/chemically induced , Erythema/pathology , Humans , Ketoconazole/administration & dosage , Ketoconazole/therapeutic use , Male , Skin/pathology , Syndrome , Tinea Pedis/complications , Tinea Pedis/drug therapy
19.
Mycoses ; 56 Suppl 1: 23-5, 2013 May.
Article in English | MEDLINE | ID: mdl-23574021

ABSTRACT

Undetected tinea pedis in a patient with diabetes can lead to serious bacterial infections with potentially serious consequences, such as foot amputations. Here we report on a 60-year-old patient with diabetes presenting with pain, severe pruritus, and malodour in the foot's interdigital area, and subsequently, diagnosed with inflammatory tinea pedis with bacterial superinfection. The patient was successfully treated with Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%; marked improvement occurred within 5 days.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Antifungal Agents/administration & dosage , Diflucortolone/analogs & derivatives , Miconazole/analogs & derivatives , Skin Diseases, Bacterial/drug therapy , Tinea Pedis/drug therapy , Administration, Topical , Diabetes Complications , Diflucortolone/administration & dosage , Humans , Male , Miconazole/administration & dosage , Middle Aged , Skin Diseases, Bacterial/complications , Superinfection/drug therapy , Tinea Pedis/complications , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...